Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 31 of 36 / 848 articles
Nicotine pouches have been around for years in Sweden. But in 2025, they crossed a threshold: from niche Scandinavian product to global mass-market phenomenon. The numbers are staggering, and the implications are profound.
The Wild West era of vaping—thousands of brands, minimal regulation, explosive growth—is ending. What's emerging is a consolidated, regulated, and increasingly corporate industry. Who survives, and what's lost?
What will the nicotine landscape look like in 2035? Based on current trends, here are ten evidence-grounded predictions—some hopeful, some alarming, all uncertain.
MPOWER measures—monitoring, smoke-free laws, cessation, warnings, ad bans, taxation—have driven smoking down dramatically. But the decline is slowing, and the remaining smokers are the hardest to reach. What comes next?
Vapers have organized—online, at the ballot box, and in the streets—to defend their access to the products they credit with saving their lives. The movement is passionate, politically diverse, and increasingly effective.
Pharmacists are the most accessible healthcare professionals in most communities, and they're uniquely positioned to deliver smoking cessation support. Why aren't we using them?
Nicotine pouches, gums, lozenges, toothpicks, and dissolving tablets—the oral nicotine category is exploding into micro-formats, each with its own user base, use case, and regulatory gray area.
The evidence for tobacco harm reduction is stronger than ever. So why does the public health establishment remain opposed? The answer lies in institutional culture, funding structures, and the psychology of expertise.
For decades, particularly among women, cigarettes have been used as a weight management tool. Understanding this connection—and offering alternatives that don't kill—is one of the most neglected aspects of smoking cessation.
If regulators ban nicotine, chemists will make something that looks like nicotine, acts like nicotine, but isn't legally 'nicotine.' The analogue pipeline is already flowing, and the regulatory system isn't ready.
Vape shop staff aren't doctors. They're not trained in addiction medicine. But every day, they guide smokers through the most important health decision of their lives. The system is improvised, unregulated, and surprisingly effective.
Indigenous peoples smoke at rates far exceeding settler populations—a direct legacy of colonial trade, displacement, and targeted marketing. Addressing this gap requires confronting history, not just promoting cessation.
Nicotine withdrawal is uncomfortable, distracting, and demoralizing—but it's also predictable, time-limited, and manageable with the right strategies. Here's what the neuroscience says about navigating the hardest part of quitting.
Japan didn't embrace vaping—nicotine e-liquid is effectively banned. Instead, it embraced heated tobacco. The Japanese experience challenges every assumption in the global nicotine debate.
Smokers take more breaks, earn less, and face increasing workplace discrimination. The smoking break is a microcosm of how nicotine addiction intersects with class, productivity, and fairness in the modern workplace.
For years, nicotine regulation hinged on a single word: 'tobacco.' When chemists figured out how to synthesize nicotine without tobacco plants, the entire regulatory framework was thrown into question.
For decades, the industry's most effective defense has been a single argument: smokers choose to smoke. The appeal to personal responsibility has been devastatingly effective at blocking regulation—and it's back.
The nicotine patch was a pharmaceutical breakthrough: a steady, continuous dose of nicotine without the peaks and troughs of smoking. Four decades later, it remains the most widely used cessation aid—and its limitations are instructive.
Smokers feel judged, stigmatized, and excluded by the very public health campaigns designed to help them quit. The result is a trust deficit that undermines cessation. Can tobacco control rebuild the relationship?
People living with HIV smoke at two to three times the general population rate, and smoking now kills more HIV-positive people than the virus itself. For this population, harm reduction isn't theoretical—it's urgent.
When Philip Morris funds a study showing vaping helps smokers quit, is it science or marketing? When the WHO funds a study showing vaping is dangerous, is it objectivity or institutional bias? The funding question is inescapable.
Progressives have led the fight against smoking for decades. But the rise of harm reduction has split the coalition—pitting public health pragmatists against precautionary-principle advocates in a battle over values.
In 2019, a mysterious lung illness killed 68 people and hospitalized nearly 3,000. EVALI triggered a panic about vaping. The cause was eventually identified. The lessons have been selectively remembered.
Nicotine use is surprisingly common among elite athletes—not for recreation, but for performance. The phenomenon challenges the simplistic narrative of nicotine as purely a harmful addiction.
Products
Select a product to view details, highlights, and technical specifications.
